PSORS3
MCID: PSR024
MIFTS: 25

Psoriasis 3 (PSORS3)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 3

MalaCards integrated aliases for Psoriasis 3:

Name: Psoriasis 3 57 12
Psoriasis Susceptibility 3 57 13
Psors3 57 12
Psoriasis 3, Susceptibility to 57

Classifications:



External Ids:

Disease Ontology 12 DOID:0111283

Summaries for Psoriasis 3

Disease Ontology : 12 A psoriasis that has material basis in variation in a region on chromosome 4q.

MalaCards based summary : Psoriasis 3, also known as psoriasis susceptibility 3, is related to psoriasis and skin disease. An important gene associated with Psoriasis 3 is PSORS3 (Psoriasis Susceptibility 3). The drugs Clobetasol and glucocorticoids have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and testes.

More information from OMIM: 601454 PS177900

Related Diseases for Psoriasis 3

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 3 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 psoriasis 11.8
2 skin disease 10.2
3 pustulosis of palm and sole 10.2
4 impetigo herpetiformis 9.7

Symptoms & Phenotypes for Psoriasis 3

Clinical features from OMIM:

601454

Drugs & Therapeutics for Psoriasis 3

Drugs for Psoriasis 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 32798 5311051
2 glucocorticoids Phase 3
3 Hormones Phase 3
4 Hormone Antagonists Phase 3
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
6
Adalimumab Approved 331731-18-1 16219006
7
Certolizumab pegol Approved 428863-50-7
8
Etanercept Approved, Investigational 185243-69-0
9 Anti-Inflammatory Agents
10 Gastrointestinal Agents
11 Immunosuppressive Agents
12 Immunologic Factors
13 Analgesics, Non-Narcotic
14 Peripheral Nervous System Agents
15 Analgesics
16 Anti-Inflammatory Agents, Non-Steroidal
17 dipyrone
18 Antipyretics
19 Antirheumatic Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Subject Preference Comparison Between Clobetasol Propionate Shampoo, 0.05% and Three Other Topical Corticosteroids in the Treatment of Moderate to Severe Scalp Psoriasis Completed NCT00438399 Phase 3 C. propionate - Corticosteroid 1;C. propionate- Corticosteroid 2;C. propionate -Corticosteroid 3;Corticosteroid 1- C. propionate;Corticosteroid 2 - C. propionate;Corticosteroid 3 - C. propionate
2 A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis Completed NCT02173301 Phase 2 XP23829 400 mg QD;XP 23829 800 mg QD;XP23829 400 mg BID;Placebo
3 An Observational Study Evaluating the Utility of Ultrasound Confirmed Enthesitis as a Prognostic Marker for Response to Biologic Therapy in Psoriatic Arthritis Recruiting NCT03955861
4 Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis Not yet recruiting NCT03889938

Search NIH Clinical Center for Psoriasis 3

Genetic Tests for Psoriasis 3

Anatomical Context for Psoriasis 3

MalaCards organs/tissues related to Psoriasis 3:

41
Skin, Lung, Testes, Tonsil

Publications for Psoriasis 3

Articles related to Psoriasis 3:

(show all 46)
# Title Authors PMID Year
1
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. 8
19684581 2009
2
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. 8
18369459 2008
3
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. 8
9858851 1999
4
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. 8
9259283 1997
5
Evidence that a locus for familial psoriasis maps to chromosome 4q. 8
8841203 1996
6
Prevalence of skin disorders and associated socio-economic factors among primary school children in the Eastern region of Saudi Arabia. 38
31431774 2019
7
Circumscribed Juvenile Pityriasis Rubra Pilaris (Type 4) Koebnerising after a Hot Water Burn: Mild Disease with Maximum Koebner Response. 38
31032794 2019
8
Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. 38
30672623 2019
9
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. 38
29596638 2018
10
Association of Psoriasis With Comorbidity Development in Children With Psoriasis. 38
29322175 2018
11
Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention. 38
29415875 2018
12
A Case of Ceftriaxone-Induced Acute Generalized Exanthematous Pustulosis/Generalized Pustular Psoriasis Overlap. 38
29681811 2018
13
Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison. 38
28762213 2017
14
Biosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies). 38
28511752 2017
15
[Evidence-based Indications for Tonsillectomy]. 38
27128404 2016
16
Indications for tonsillectomy stratified by the level of evidence. 38
28025609 2016
17
Association of Extrahepatic Manifestations with Autoimmune Hepatitis. 38
26641498 2015
18
Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. 38
24470406 2014
19
Respiratory failure due to infliximab induced interstitial lung disease. 38
23969008 2013
20
Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. 38
23330679 2013
21
[Guidelines for high-quality use of biologic therapies in adults with plaque psoriasis]. 38
22985925 2012
22
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. 38
22113483 2012
23
New-onset psoriasis associated with adalimumab: a report of two cases. 38
21971280 2011
24
Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts. 38
21818512 2011
25
A case series of kaposi's varicelliform eruption in dermatology in-patients in a tertiary care centre. 38
21572809 2011
26
Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies. 38
20520526 2010
27
Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. 38
20513160 2010
28
[Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation]. 38
19361697 2009
29
A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. 38
19002344 2008
30
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. 38
17706322 2007
31
Psoriasis of the face and flexures. 38
17907013 2007
32
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. 38
16965422 2006
33
Does inflammatory linear verrucous epidermal nevus represent a segmental type 1/type 2 mosaic of psoriasis? 38
16484814 2006
34
Evaluation of the IRF-2 gene as a candidate for PSORS3. 38
14962090 2004
35
Psoriatic nails: a prospective clinical study. 38
12879333 2003
36
Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. 38
12485440 2002
37
[Efficacy of tonsillectomy on psoriasis and tonsil histology]. 38
11766391 2001
38
Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. 38
11348461 2001
39
Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris. 38
10877128 2000
40
Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. 38
7611794 1995
41
[Interferon and diseases]. 38
7523746 1994
42
Methimazole (2-mercapto 1-methyl imidazole) in psoriasis--results of an open trial. 38
8324273 1993
43
[The initial clinical experience of using Ovosorb antiprotease hemosorbent in the combined treatment of dermatoses]. 38
1805413 1991
44
Hidden psoriatic arthritis in seronegative oligoarthritis: a 14-year follow-up study. 38
2612119 1989
45
Cascade filtration: clinical application in 26 patients with immune complex and IgM mediated diseases. 38
6230324 1983
46
Psoriasis: odd varieties in the adult. 38
161135 1979

Variations for Psoriasis 3

Expression for Psoriasis 3

Search GEO for disease gene expression data for Psoriasis 3.

Pathways for Psoriasis 3

GO Terms for Psoriasis 3

Sources for Psoriasis 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....